** Shares of drugmaker Pfizer PFE.N rise ~2% to $26.72 premarket

** Co reports Q4 adj. profit of 63 cents per share, above analysts' est. of 47 cents, according to data compiled by LSEG, driven by strong sales of its heart disease drug and COVID-19 vaccine sales

** Co posts Q4 sales of $17.76 bln vs analysts' est. of $17.36 bln - LSEG

** Q4 sales of heart disease drug, sold as Vyndaqel and Vyndamax, came in at $1.55 bln, above estimates of $1.48 bln - LSEG

** COVID vaccine Comirnaty brought in sales of $3.38 bln, above analysts' est. of $3.10 bln - LSEG

** PFE fell 10.8% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))